<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02910037</url>
  </required_header>
  <id_info>
    <org_study_id>P0509948</org_study_id>
    <nct_id>NCT02910037</nct_id>
  </id_info>
  <brief_title>Precision Diagnosis of Acute Infectious Diseases; Neuroinflammatory Cohort</brief_title>
  <acronym>PDAID</acronym>
  <official_title>Clinical Implementation of Metagenomic Next-Generation Sequencing for Precision Diagnosis of Acute Infectious Diseases; Neuroinflammatory Cohort</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of California, San Francisco</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>California Initiative to Advance Precision Medicine</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Sandler Foundation</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Bowes Foundation</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Charles and Helen Schwab Foundation</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of California, Davis</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of California, Los Angeles</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Children's Hospital Los Angeles</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Children's Hospital Colorado</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>St. Jude Children's Research Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Children's Research Institute</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of California, Berkeley</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>DNAnexus, Inc.</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Syapse, Inc.</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of California, San Francisco</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_unapproved_device>Yes</is_unapproved_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study aims to use a clinically validated metagenomic next-generation sequencing (mNGS)
      assay to provide a demonstration of precision medicine for diagnosis of acute infectious
      disease in hospitalized patients. From June 2016 to June 2017, 200 patients will be enrolled
      from multiple hospitals in California and outside of California. Patients will be evaluated
      to determine the impact on the mNGS assay on diagnostic yield, hospital costs and clinical
      outcomes.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study aims to use a clinically validated metagenomic next-generation sequencing (mNGS)
      assay to provide a demonstration of precision medicine for diagnosis of acute infectious
      disease in hospitalized patients, with the goal of directly impacting clinical care and
      improving patient mortality. This diagnostic test has been previously validated in a Clinical
      Laboratory Improvement Amendments (CLIA)-certified laboratory, the University of California,
      San Francisco Clinical Microbiology Laboratory. From June 2016 to June 2017, investigators
      will prospectively enroll 200 patients from multiple hospitals in California (University of
      California, San Francisco; University of California, Los Angeles; University of California,
      Davis; Children's Hospital Los Angeles) and outside California (Children's National Medical
      Center, Children's Hospital Colorado, St. Jude Children's Research Hospital) for mNGS
      testing, and evaluate the impact on the assay on diagnostic yield, hospital costs and
      clinical outcomes.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">June 1, 2016</start_date>
  <completion_date type="Actual">July 31, 2017</completion_date>
  <primary_completion_date type="Actual">July 31, 2017</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Impact on clinical reasoning and management</measure>
    <time_frame>within 1 month of patient enrollment in study</time_frame>
    <description>Investigators will evaluate impact of mNGS assay by clinician surveys and Clinical Microbial Sequencing Board (CMSB) feedback and discussion</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Cost of care for patients hospitalized for encephalitis/meningitis</measure>
    <time_frame>from admission to 1 month post discharge for each patient during the enrollment period of study (ends June 2017)</time_frame>
    <description>Two data sets will be used during the duration of this study. Claims data will be used to analyze 5 years of retrospective cost data on patients hospitalized with encephalitis and/or meningitis. This data set will be used to establish a reference for total cost of care, average length of stay and number of invasive procedures. Statistical models will be proposed to evaluate the cost-effectiveness based on time of intervention of the mNGS assay for pathogen detection (i.e. at presentation in emergency department, at time of repeat lumbar puncture, or based on hospital location - Emergency Department to Intensive Care Unit). Patients enrolled in this research study will also be consented to sharing billing data with the investigators. This will be evaluated and compared to the retrospective claims data.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical outcomes: time to diagnosis</measure>
    <time_frame>from admission to 1 month post discharge for each patient during the enrollment period of study (ends June 2017)</time_frame>
    <description>Investigators will review medical records to determine time to definitive diagnosis for patients enrolled in the study.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical outcomes: length of stay</measure>
    <time_frame>from admission to 1 month post discharge for each patient during the enrollment period of study (ends June 2017)</time_frame>
    <description>Investigators will review medical records to determine length of stay including discharge to rehab facilities.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical outcomes: treatments given and time to targeted therapy</measure>
    <time_frame>from admission to 1 month post discharge for each patient during the enrollment period of study (ends June 2017)</time_frame>
    <description>Investigators will review medical records and discuss with treatment teams to determine therapies given and treatment strategy to measure time to targeted therapy.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical outcomes: number of diagnostic tests and invasive procedures</measure>
    <time_frame>from admission to 1 month post discharge for each patient during the enrollment period of study (ends June 2017)</time_frame>
    <description>Investigators will review medical records and discuss with treatment teams to track the number of diagnostic tests send and invasive procedures performed before definitive diagnosis established for patients enrolled in study.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">204</enrollment>
  <condition>Encephalitis</condition>
  <condition>Meningitis</condition>
  <arm_group>
    <arm_group_label>patients enrolled for mNGS testing</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients with meningitis and/or encephalitis will be enrolled in this study in order to analyze the clinical utility of mNGS for pathogen detection. There is no control group for this study (Investigators will identify historical controls by retrospective chart review and clinical reimbursement documents).</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>mNGS for pathogen detection</intervention_name>
    <description>This assay is a laboratory-validated metagenomic test for comprehensive detection of viruses, bacteria, fungi, and parasites in clinical samples.</description>
    <arm_group_label>patients enrolled for mNGS testing</arm_group_label>
    <other_name>Sequence-Based Ultrarapid Pathogen Identification (SURPI)+</other_name>
    <other_name>UCSF metagenomic next-generation sequencing testing</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Exclusions:

          -  Patients on a 5150 or 5250 psychiatric hold

          -  Prisoners

          -  University of California employees / students or close associates of any of the key
             personnel on the study

          -  Outpatients and/or patients with chronic illness

        Inclusion:

        Demographic Criteria

          1. Age: any (no age limit)

          2. Language: any (with the use of interpreting services for obtaining consent)

        For the following, the infectious syndromes include meningitis, encephalitis, fever,
        sepsis, and pneumonia:

        Clinical Criteria

          1. Hospital admission or transfer with diagnosis of an presumed infectious syndrome or
             clinical presentation consisting with an infectious syndrome, as defined below:

               -  Meningitis: fever &gt;38°C and abnormal imaging or CSF pleocytosis (CSF white blood
                  cell count (WBC) &gt; 5 /mm^3) +/- stiff neck, +/- headache, +/- seizure

               -  Encephalitis: pleocytosis and at least one of the following: altered mental
                  status, seizures, new onset of focal neurologic findings, abnormal EEG, acute
                  brain abnormalities on neuroimaging

          2. No known diagnosis of non-infectious etiology responsible for symptoms

          3. Time of enrollment: within 7 days of onset of symptoms, either initial presentation or
             acute exacerbation of presumed infectious syndrome.

        Specimen Criteria

          1. cerebrospinal fluid available within 7 days of symptom onset AND within 3 days of
             hospital admission or transfer unless evidence for acute exacerbation as defined by
             abrupt decline in clinical status, worsening pleocytosis or other laboratory
             parameters

          2. Minimum of 600 microliters (uL) of clinical sample, stored at 4 degrees Celsius (C) no
             more than 5 days (ideally frozen in -70 degrees Celsius within 24 hours of collection)

          3. No more than 3 freeze-thaw cycles
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>110 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Charles Y Chiu, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of California, San Francisco</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Hannah Sample, BS</last_name>
    <role>Study Director</role>
    <affiliation>University of California, San Francisco</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of California, Davis Medical Center</name>
      <address>
        <city>Davis</city>
        <state>California</state>
        <zip>95616</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Children's Hospital Los Angeles</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90027</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of California, Los Angeles Medical Center</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90095</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of California, San Francisco Medical Center</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94116</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Children's Hospital Colordao</name>
      <address>
        <city>Denver</city>
        <state>Colorado</state>
        <zip>80045</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Children's National Medical Center</name>
      <address>
        <city>Washington</city>
        <state>District of Columbia</state>
        <zip>20010</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. Jude Children's Research Hospital</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37212</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://chiulab.ucsf.edu</url>
    <description>brief description of PDAID study and referral link</description>
  </link>
  <link>
    <url>http://www.ciapm.org/project/precision-diagnosis-acute-infectious-diseases</url>
    <description>summary of the PDAID project, sponsored by the California Initiative to Advance Precision Medicine</description>
  </link>
  <link>
    <url>https://www.youtube.com/watch?v=OFYSEowGfeI</url>
    <description>video describing metagenomic next-generation sequencing and its use for diagnosis of infections</description>
  </link>
  <link>
    <url>http://nextgendiagnostics.ucsf.edu</url>
    <description>The UCSF Center for Next-Gen Precision Diagnostics</description>
  </link>
  <reference>
    <citation>Wilson MR, Naccache SN, Samayoa E, Biagtan M, Bashir H, Yu G, Salamat SM, Somasekar S, Federman S, Miller S, Sokolic R, Garabedian E, Candotti F, Buckley RH, Reed KD, Meyer TL, Seroogy CM, Galloway R, Henderson SL, Gern JE, DeRisi JL, Chiu CY. Actionable diagnosis of neuroleptospirosis by next-generation sequencing. N Engl J Med. 2014 Jun 19;370(25):2408-17. doi: 10.1056/NEJMoa1401268. Epub 2014 Jun 4.</citation>
    <PMID>24896819</PMID>
  </reference>
  <reference>
    <citation>Greninger AL, Messacar K, Dunnebacke T, Naccache SN, Federman S, Bouquet J, Mirsky D, Nomura Y, Yagi S, Glaser C, Vollmer M, Press CA, Kleinschmidt-DeMasters BK, Dominguez SR, Chiu CY. Clinical metagenomic identification of Balamuthia mandrillaris encephalitis and assembly of the draft genome: the continuing case for reference genome sequencing. Genome Med. 2015 Dec 1;7:113. doi: 10.1186/s13073-015-0235-2. Erratum in: Genome Med. 2016;8(1):1. Klenschmidt-DeMasters, Bette K [corrected to Kleinschmidt-DeMasters, Bette K].</citation>
    <PMID>26620704</PMID>
  </reference>
  <reference>
    <citation>Naccache SN, Peggs KS, Mattes FM, Phadke R, Garson JA, Grant P, Samayoa E, Federman S, Miller S, Lunn MP, Gant V, Chiu CY. Diagnosis of neuroinvasive astrovirus infection in an immunocompromised adult with encephalitis by unbiased next-generation sequencing. Clin Infect Dis. 2015 Mar 15;60(6):919-23. doi: 10.1093/cid/ciu912. Epub 2015 Jan 7.</citation>
    <PMID>25572898</PMID>
  </reference>
  <reference>
    <citation>Greninger AL, Naccache SN, Messacar K, Clayton A, Yu G, Somasekar S, Federman S, Stryke D, Anderson C, Yagi S, Messenger S, Wadford D, Xia D, Watt JP, Van Haren K, Dominguez SR, Glaser C, Aldrovandi G, Chiu CY. A novel outbreak enterovirus D68 strain associated with acute flaccid myelitis cases in the USA (2012-14): a retrospective cohort study. Lancet Infect Dis. 2015 Jun;15(6):671-82. doi: 10.1016/S1473-3099(15)70093-9. Epub 2015 Mar 31.</citation>
    <PMID>25837569</PMID>
  </reference>
  <reference>
    <citation>Naccache SN, Federman S, Veeraraghavan N, Zaharia M, Lee D, Samayoa E, Bouquet J, Greninger AL, Luk KC, Enge B, Wadford DA, Messenger SL, Genrich GL, Pellegrino K, Grard G, Leroy E, Schneider BS, Fair JN, Martínez MA, Isa P, Crump JA, DeRisi JL, Sittler T, Hackett J Jr, Miller S, Chiu CY. A cloud-compatible bioinformatics pipeline for ultrarapid pathogen identification from next-generation sequencing of clinical samples. Genome Res. 2014 Jul;24(7):1180-92. doi: 10.1101/gr.171934.113. Epub 2014 Jun 4.</citation>
    <PMID>24899342</PMID>
  </reference>
  <reference>
    <citation>Wilson MR, Shanbhag NM, Reid MJ, Singhal NS, Gelfand JM, Sample HA, Benkli B, O'Donovan BD, Ali IK, Keating MK, Dunnebacke TH, Wood MD, Bollen A, DeRisi JL. Diagnosing Balamuthia mandrillaris Encephalitis With Metagenomic Deep Sequencing. Ann Neurol. 2015 Nov;78(5):722-30. doi: 10.1002/ana.24499. Epub 2015 Aug 24.</citation>
    <PMID>26290222</PMID>
  </reference>
  <verification_date>April 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 13, 2016</study_first_submitted>
  <study_first_submitted_qc>September 19, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 21, 2016</study_first_posted>
  <last_update_submitted>April 11, 2018</last_update_submitted>
  <last_update_submitted_qc>April 11, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">April 13, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>metagenomic next-generation sequencing</keyword>
  <keyword>microbiological diagnosis</keyword>
  <keyword>bacterial infections</keyword>
  <keyword>viral infections</keyword>
  <keyword>fungal infections</keyword>
  <keyword>parasitic infections</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Meningitis</mesh_term>
    <mesh_term>Encephalitis</mesh_term>
    <mesh_term>Communicable Diseases</mesh_term>
    <mesh_term>Infection</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>All genomic / metagenomic sequencing data from this study will be made available either at NIH Sequence Read Archive or NIH database of Genotypes and Phenotypes (dbGaP), depending on whether human sequence data is included. The investigators intend to make de-identified ancillary clinical, laboratory, and radiographic data available as well upon request.</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

